During the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo in Atlanta, Thermo Fisher Scientific, Waltham, Mass., showcased its expanding portfolio of instruments, assays, controls, and related technologies for increasing speed, performance, and flexibility within clinical and research laboratories.
During AACC, the company is also donating equipment for AACC’s COVID-19 Immunity Study, enabling onsite serology testing that will analyze immune responses to SARS-CoV-2 vaccination among participants.
“The pandemic has been a catalyst for innovation across our laboratory testing portfolio, and progress hasn’t been limited to COVID-19-related capabilities,” says Gianluca Pettiti, senior vice president and president of specialty diagnostics for Thermo Fisher Scientific. “During AACC, we’re showcasing new instruments, assays, and controls for COVID-19, as well as new assays for drugs of abuse testing and the most common form of lupus, and demonstrating our latest mass spectrometry-based instruments for both research and clinical applications.”
Supporting Increased COVID-19 Testing
To support ongoing COVID-19 testing, Thermo Fisher is launching two PCR-based kits: the Applied Biosystems TaqPath COVID-19 Fast PCR Combo Kit 2.0 and the Applied Biosystems TaqPath COVID-19 RNase P Combo Kit 2.0. The kits target eight genes across three regions of the virus that causes COVID-19. Additionally, the Mu variant is now included in the company’s existing Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel.
The company is also launching the Thermo Scientific AcroMetrix SARS-CoV-2 Control for monitoring extraction, amplification, and detection steps for SARS-CoV-2 assays.
The Applied Biosystems QuantStudio Absolute Q Digital PCR System, launched earlier this month, is the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes. The underlying technology powering this system is already in use by biotech companies and academic institutions for longitudinal monitoring of cancer-driven mutations in liquid biopsy, precise quantification of gene inserts for cell therapy development and copy number variation studies for earlier identification of genetic conditions in newborns.
To better assess the performance of next-generation sequencing-based assays that can detect somatic mutations, Thermo Fisher is introducing the Thermo Scientific AcroMetrix Oncology Hotspot Control, a highly multiplexed quality control.
Finally, the Thermo Scientific EliA SmDP-S test, just cleared by the U.S. Food and Drug Administration, aids in the diagnosis of Systemic Lupus Erythematosus (SLE), the most common type of lupus.
Improving Drugs of Abuse Testing
To meet increasing demand for drug screening in clinical and drug court laboratories, Thermo Fisher Scientific has launched a 510(k) cleared fentanyl assay, DRI Fentanyl II, and partnered with Mindray to provide two new high-performance analyzers, the Mindray BS480 and Mindray BA800M. These analyzers and an expanding assay portfolio equip new and existing customers with the flexibility to run up to 800 tests per hour.
Enabling Mass Spectrometry-Based Workflow Adoption
For laboratories adopting or perfecting mass spectrometry-based workflows, the new Thermo Scientific TSQ Plus triple quadrupole mass spectrometer (MS) portfolio, which includes the TSQ Altis Plus, TSQ Quantis Plus and TSQ Fortis Plus MS, addresses a range of applications, from targeted quantitation to cutting-edge research within pharmaceutical, food, and environmental laboratories facing regulatory requirements for lower detection limits.
For more information, visit www.thermofisher.com.
Featured Image: The Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel features a customizable menu of verified real-time PCR assays for identification of SARS-CoV-2 mutations, such as with the Delta, Lambda, and Mu variants. Photo: Thermo Fisher